Every 8-K that Acurx Pharmaceuticals, Inc. (ACXP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ACXP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACXP filings page.
Acurx Pharmaceuticals is raising equity capital through a registered direct offering with a concurrent private placement of warrants. The company agreed to sell 816,068 common shares at $3.03 per share and pre-funded warrants for up to 9,017 shares at $3.029, for aggregate gross proceeds of about $2.5 million before fees.
In the private placement, investors will receive Series H warrants to purchase up to 1,650,170 shares of common stock at an exercise price of $2.78 per share, exercisable immediately and expiring 24 months after the resale registration becomes effective. If these warrants are fully exercised for cash, the company could receive up to an additional $4.6 million.
The company plans to use net proceeds for working capital and general corporate purposes, has agreed to a 15-day lock-up on most new equity issuances after closing, and will avoid variable rate transactions for one year except for a potential at-the-market program and an equity line of credit.
Acurx Pharmaceuticals is reducing cash compensation and advancing its lead antibiotic program. Effective April 1, 2026, the Compensation Committee approved fully voluntary 10% base salary cuts for senior executives, including the CEO and Executive Chairman, and a 10% cut to cash retainers for non-employee directors, while equity incentives remain unchanged.
The company also launched a new clinical initiative to expand ibezapolstat into recurrent C. difficile infection with an open-label pilot trial in up to 20 multiply‑recurrent patients, with start-up activities later this month and first-patient enrollment expected in the fourth quarter, intended to inform a planned Phase 3 registration trial and a future FDA LPAD approval request.
Acurx Pharmaceuticals, Inc. filed a Form 8-K dated September 22, 2025 reporting a material event: the company attached a Certificate of Amendment to the Certificate of Incorporation that is dated September 19, 2025. The filing notes inclusion of the cover page Inline XBRL tags and is signed by David P. Luci, President and Chief Executive Officer. The report appears limited to the corporate charter amendment and related filing mechanics; no financial statements, earnings data, or transaction details are included in the provided text.
Acurx Pharmaceuticals, Inc. stockholders approved several key items at a special meeting held on September 16, 2025. Of 30,524,540 common shares outstanding as of the July 21, 2025 record date, 19,365,579 shares, or about 63.44%, were represented, establishing a quorum. Stockholders approved, for Nasdaq Listing Rule 5635(d) purposes, issuing common shares underlying Series G-2 warrants that could equal 20% or more of common stock outstanding before those warrants were issued. They also approved increasing authorized common shares from 200,000,000 to 250,000,000, subject to the board’s discretion, and approved the potential adjournment of the meeting to solicit additional proxies if needed.
Acurx Pharmaceuticals, Inc. (ACXP) filed an 8-K announcing a warrant-inducement transaction dated 17 June 2025.
Key cash component: a single holder exercised 4,445,435 existing Series A-D warrants at a reduced price of $0.60 per share, delivering ~$2.67 million gross / ~$2.3 million net cash to Acurx after a 7% placement fee and expenses.
New equity overhang: In exchange for the price reduction, Acurx granted the same holder
- Series G-1 warrants: 6,223,609 shares, exercisable immediately, $0.425 strike, 5-year term.
- Series G-2 warrants: 2,667,261 shares, exercisable post-stockholder approval, $0.425 strike, 5-year term from approval.
Potential dilution: including the exercised shares, up to ~13.6 million shares (4.45 M issued + 9.16 M new warrants) could enter the float, subject to ownership caps (4.99%/9.99%) and future exercise decisions.
Timing & registration: Closing targeted for 20 June 2025. Acurx must file a resale registration statement for the New Warrant Shares within 30 days and seek effectiveness within 60 days. For 45 days, the company is restricted from issuing additional equity and, for 90 days, from variable-rate financings (with limited exceptions).
Use of proceeds: general corporate and working-capital purposes.
Other terms: New warrants allow cashless exercise if resale registration is unavailable, include customary anti-dilution adjustments, lack an exchange listing, and contain standard fundamental-transaction protections.
Investor takeaway: The deal supplies modest near-term liquidity but meaningfully expands future share supply at sub-$1 strike prices, creating dilution risk while limiting additional near-term equity issuance.